Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome01:23

Irritable Bowel Syndrome

DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Gastric Electrical Stimulation on Economic Burden of Refractory Vomiting: A French Nationwide Multicentre Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2020
Same author

Responses to the Letter to the Editor by Brusciano et al.

Neurogastroenterology and motility·2020
Same author

Stress-induced intestinal barrier dysfunction is exacerbated during diet-induced obesity.

The Journal of nutritional biochemistry·2020
Same author

Anxiety and Depression Profile Is Associated With Eating Disorders in Patients With Irritable Bowel Syndrome.

Frontiers in psychiatry·2020
Same author

European society of neurogastroenterology and motility guidelines on functional constipation in adults.

Neurogastroenterology and motility·2019
Same author

Gastric Electrical Stimulation Reduces Refractory Vomiting in a Randomized Crossover Trial.

Gastroenterology·2019

Related Experiment Video

Updated: Jul 15, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

[Irritable bowel syndrome: current treatment options].

Philippe Ducrotté1

  • 1Département d'hépatogastroentérologie et de nutrition, Centre hospitalier, ADEN EA 3234 / IFRMP 23, Rouen. philippeducrotte@numericable.fr

Presse Medicale (Paris, France : 1983)
|May 11, 2007
PubMed
Summary

Irritable bowel syndrome (IBS) treatment focuses on abdominal pain relief, with limited drug options and challenges in dietary approaches. Emerging treatments target visceral hypersensitivity, including antidepressants and future probiotics.

More Related Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Related Experiment Videos

Last Updated: Jul 15, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Psychosomatic Medicine

Context:

  • Irritable bowel syndrome (IBS) presents significant challenges in pain management.
  • Current pharmacological treatments have limitations, including reimbursement issues and side effects.
  • Dietary interventions for IBS lack consistent evidence and can be problematic.

Purpose:

  • To review current and emerging treatment strategies for irritable bowel syndrome (IBS).
  • To highlight the importance of addressing visceral hypersensitivity in IBS management.
  • To explore both pharmacological and non-pharmacological therapeutic options.

Summary:

  • Abdominal pain relief is the primary goal in IBS management, with no single standout drug.
  • Antispasmodics and alverine citrate are initial options, but face reimbursement hurdles.
  • Treatments targeting visceral hypersensitivity, such as low-dose tricyclic antidepressants, show promise.
  • Serotonergic drugs like tegaserod may become available, while others (alosetron, cilansetron) were halted due to safety concerns.
  • Non-drug therapies including hypnosis, psychotherapy, relaxation, yoga, and future probiotics offer alternative management avenues.

Impact:

  • Provides a comprehensive overview of IBS treatment landscape.
  • Informs clinicians about diverse therapeutic options beyond traditional medications.
  • Suggests future research directions, particularly in probiotics and personalized dietary approaches.
  • Emphasizes the multifactorial nature of IBS, requiring tailored patient management.